Lower hemoglobin A1c levels alone don’t appear to increase mortality risk with intensive glucose control, subanalyses of two major diabetes trials revealed. Each 1% lower average HbA1c was associated with a 56% lower relative risk of mortality. Diabetes patients had reduced composite cardiovascular event and mortality rates with intensive glucose …

Insulin sensitivity, beta-cell function, and blood glucose may provide telltale signs of impending Type 2 diabetes up to five years before onset, researchers affirmed.

Last year at the ADA 68th ADA Scientific Sessions, results from the ACCORD and VADT studies indicated that tight glucose control increased the risk of cardiovascular death. This year they reviewed the results again and found that the headlines were unfounded. Now they have reversed their opinions and are saying …

For diabetic retinopathy screening, telemedicine and photographing fewer fields allow for faster detection for more patients, researchers said.

The FDA has informed us that some stolen vials of the long-acting insulin Levemir made by Novo Nordisk Inc., are being sold in the U.S. market. They may not have been stored and handled properly, and may be dangerous for patients to use. The agency is advising patients who use …

After two decades on the rise, retinopathy now affects more than a third of all diabetes patients, according to the latest nationally representative estimate.

A novel continuous glucose monitor that uses fluorescence to provide a read-out of blood sugar appears to be accurate, especially in the hypoglycemic range, researchers said at ADA.

Three investigational diet drugs hold promise for preventing and treating diabetes. The findings show that the drugs can help “halt the progression towards Type 2 diabetes.

Novo Nordisk experimental diabetes drug liraglutide was significantly better at helping patients control blood sugar than an older common medicine after two years of treatment, according to data from a clinical trial.

We are back from the 69th ADA Scientific Sessions and there were a lot of new studies, practice pearls and products in development. We have stocked this weeks issue with some of the early highlights and will have more over the next few weeks as our editorial staff has time …